Drug
Gallium-68 clinical trials
- studies test it
- 52
- open now
- 37
- in phase 3
- 5
- first study started
- 2010
Keep track of what changes. Save the Gallium-68 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
52 studies that test it; most in 2024 (16)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 5 |
| 2024 | 16 |
| 2025 | 10 |
| 2026 | 13 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 19
- Phase 1
- 14
- Phase 2
- 15
- Phase 3
- 5
- No phase
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 15 · Other 37
University of California, Davis (4) · Philogen S.p.A. (4) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (4) · RenJi Hospital (4) · Peking University Cancer Hospital & Institute (3) · Novartis Pharmaceuticals (2) · Peking Union Medical College Hospital (2) · John O. Prior (2)
Often tested with
Tested in the same studies.
SAR425899 (1) · Lutetium-177 (1) · ALF-NOTA-FAPI-04 F-18 (1)
Studies
Open first, then newest update. How each study uses Gallium-68 is read from its arms, and is right about nine times in ten.
Testing it · 52
- Diagnostic Performance of ACP3-Targeted PET Imaging in Patients With Primary and Recurrent Prostate Cancer: An Open-Label, Single-Arm, Single-Center StudyNot yet recruitingPhase 2Yong HeNCT07830212Written as [68Ga]Ga-OncoACP3
- Dose Optimization and Diagnostic Performance in Prostate Cancer (SPARROW [Staging Prostate Cancer With Advanced RM2 Radiotracer Oncologic Workup])RecruitingPhase 2/3Lantheus Medical ImagingNCT07831824Written as [68Ga]-LNTH-2401
- [68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology IndicationsRecruitingPhase 2Blue Earth DiagnosticsNCT07702292Written as [68Ga]BED003
- [68Ga]Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic/Advanced Invasive Lobular Breast Cancer (LBC)RecruitingPhase 1University of California, DavisNCT07020806Written as [68Ga]Ga DOTA-5G
- Molecularly Targeted Theranostic Approach for the Detection and Treatment of Metastatic CarcinomasRecruitingPhase 1University of California, DavisNCT06389123Written as [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.
- Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With CancerNot yet recruitingEarly Phase 1Lumina Pharmaceuticals IncNCT07781852Written as [68Ga]CM500
- A Phase I Study of [68Ga]Ga-DWJ155 in Patients With Breast and Lung CancersRecruitingPhase 1Novartis PharmaceuticalsNCT07117214Written as [68Ga]Ga-DWJ155
- Establishment and Clinical Transformation of ADC Drug Efficacy Evaluation System for Breast Cancer Based on Molecular ImagingRecruitingNot applicablePeking University Cancer Hospital & InstituteNCT06715020Written as [68Ga]Ga-TTP
- Clinical Evaluation of [68Ga]Ga-ELI411 PET Imaging in Adult Patients With Solid TumorsEnrolling by invitationEarly Phase 1Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNCT07741006Written as [68Ga]Ga-ELI411
- Clinical Evaluation of [68Ga]Ga-FFD PET Imaging in Healthy Volunteers and Patients With Solid TumorsNot yet recruitingEarly Phase 1Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNCT07708103Written as [68Ga]Ga-FFD
- A Study to Evaluate the Human Biodistribution and Dosimetry of the Radionuclide Labeled IR199 in Patients With Gastric Cancer and Pancreatic CancerRecruitingEarly Phase 1Huashan HospitalNCT07707531Written as [68Ga]/ [131I]-IR199
- A Clinical Study of [68Ga]Ga-ELI421 Injection PET Imaging in Patients With Prostate CancerRecruitingPhase 1/2Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNCT07689656Written as [68Ga]Ga-ELI421 injection
- Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)RecruitingPhase 2/3GE HealthcareNCT07219238Written as GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT)
- First-in-human Diagnostic Imaging Profile of the Theranostic Pair [68Ga]Ga-DOTA-STR-17126 and Low Dose [177Lu] Lu-DOTA-STR-17126 in Patients With Advanced or Metastatic CancerRecruitingEarly Phase 1Integrated Haematology and Oncology NetworkNCT07608848Written as [68Ga]Ga-DOTA-STR-17126
- A Phase I Study to Evaluate the Safety and Dosimetry of Imaging With 68Ga-OncoACP3 in Prostate CancerRecruitingPhase 1Philogen S.p.A.NCT07600554Written as [68Ga]Ga-OncoACP3
- Trop2-targeted immunoPET Imaging of Solid TumorsRecruitingPhase 2/3RenJi HospitalNCT06851663Written as [68Ga]Ga-NOTA-T4
- CD70-targeted immunoPET Imaging of Malignant CancersRecruitingPhase 2RenJi HospitalNCT06852638Written as [68Ga]Ga-NOTA-R8B4
- Single Microdose Trial- CXCR4 PET Tracer - Pharmacokinetics and Pharmacodynamics of [68Ga]Ga-R54, a Radiopharmaceutical Directed Toward CXCR4 in Patients With Advanced Solid Neoplasia.RecruitingEarly Phase 1National Cancer Institute, NaplesNCT07577206Written as [68Ga]Ga-R54 PET/CT
- Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted TherapyRecruitingEarly Phase 1Vanderbilt-Ingram Cancer CenterNCT06828588Written as [68Ga]Ga-ABY-025
- [68Ga]Ga-FAPI-46 in Staging of Head and Neck CarcinomasRecruitingPhase 2John O. PriorNCT06794372Written as [68Ga]Ga-FAPI-46 PET/CT
See all 52 studies that test Gallium-68 →
Given in every arm · 11 — Gallium-68 is usual care beside what is tested
- An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.RecruitingPhase 3Novartis PharmaceuticalsNCT05939414Written as gallium (68Ga) gozetotide (25μg)
- A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid TumorsRecruitingPhase 1/2Lumara Bio Oncologics GmbHNCT05706129Written as [68Ga]Ga-DPI-4452
- Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal CancersRecruitingPhase 1Novartis PharmaceuticalsNCT06562192Written as [68Ga]Ga-NNS309
- A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.Active, not recruitingPhase 1/2Novartis PharmaceuticalsNCT06247995Written as [68Ga]Ga-NeoB
- NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.Active, not recruitingPhase 1Novartis PharmaceuticalsNCT06379217Written as [68Ga]Ga-PSMA-11
- Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent GlioblastomaActive, not recruitingPhase 1Novartis PharmaceuticalsNCT05739942Written as [68Ga]Ga-NeoB
- A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.Active, not recruitingPhase 1Novartis PharmaceuticalsNCT05109728Written as [68Ga]Ga-DOTA-TATE
- [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast CancerActive, not recruitingPhase 1Novartis PharmaceuticalsNCT05870579Written as [68Ga]Ga-NeoB
- A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and AtezolizumabActive, not recruitingPhase 1/2Novartis PharmaceuticalsNCT05142696Written as [68Ga]Ga-DOTA-TATE
- A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate CancerActive, not recruitingPhase 2Novartis PharmaceuticalsNCT05658003Written as [68Ga]Ga-PSMA-11
- Study of Diagnostic Performance of [18F]CTT1057 in BCRCompletedPhase 3Novartis PharmaceuticalsNCT04838613Written as [68Ga]Ga-PSMA-11
Codes
What other systems call Gallium-68 · ClinicalTrials.gg INT000637
- MeSH (NLM) C000615430Gallium-68One source NLM
- UNII (FDA) 98B30EPP5SGALLIUM GA-68Confirmed NLM, Wikidata
- Wikidata Q2516934gallium-68Confirmed NLM, Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000615430 | Gallium-68 | One source NLM |
| UNII (FDA) | 98B30EPP5S | GALLIUM GA-68 | Confirmed NLM, Wikidata |
| Wikidata | Q2516934 | gallium-68 | Confirmed NLM, Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.